NYSE: IBO
IMPACT BIOMEDICAL INC.CIK 0001834105 · SIC 2834 · Pharmaceutical Preparations
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade IBO commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed Aug 7, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Condensed Consolidated Statements of Operations (Unaudited)
| Description | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Revenue: | ||||
| Biotech retail sales | 3,000 | 7,000 | 10,000 | 7,000 |
| Total revenue | 3,000 | 7,000 | 10,000 | 7,000 |
| Costs and expenses: | ||||
| Cost of revenue | 1,000 | 1,000 | 1,000 | 1,000 |
| Sales, general and administrative compensation (inclusive of stock-based compensation) | 167,000 | 246,000 | 1,786,000 | 495,000 |
| Sales and marketing | - | 1,000 | 1,000 | 20,000 |
| Professional Fees | 92,000 | 411,000 | 350,000 | 634,000 |
| Research and development | 76,000 | 75,000 | 123,000 | 178,000 |
| Depreciation and Amortization | 284,000 | 288,000 | 569,000 | 571,000 |
| Rent and utilities | 18,000 | 18,000 | 36,000 | 37,000 |
| Other operating expenses | 67,000 | 120,000 | 134,000 | 236,000 |
| Total costs and expenses | 705,000 | 1,160,000 | 3,000,000 | 2,172,000 |
| Operating loss | (702,000) | (1,153,000) | (2,990,000) | (2,165,000) |
| Other income (expense): | ||||
| Interest income | 2,000 | 3,000 | 7,000 | 7,000 |
| Change in fair value of note payable, related party | - | (12,942,000) | - | (12,942,000) |
| Interest expense | - | (260,000) | - | (531,000) |
| Loss from operations before income taxes | (700,000) | (14,352,000) | (2,983,000) | (15,631,000) |
| Income tax benefit | - | - | - | - |
| Net loss | (700,000) | (14,352,000) | (2,983,000) | (15,631,000) |
| Loss (income) from operations attributed to noncontrolling interest | 1,000 | 6,000 | (2,000) | 17,000 |
| Net loss attributable to common stockholders | (699,000) | (14,346,000) | (2,985,000) | (15,614,000) |
| Loss per common share: | ||||
| Basic | (0.01) | (1.18) | (0.03) | (1.29) |
| Diluted | (0.01) | (1.18) | (0.03) | (1.29) |
| Shares used in computing loss per common share: | ||||
| Basic | 107,821,231 | 12,185,412 | 107,803,551 | 12,124,146 |
| Diluted | 107,821,231 | 12,185,412 | 107,803,551 | 12,124,146 |
Condensed Consolidated Balance Sheets
| Description | June 30, 2026 (unaudited) | December 31, 2025 |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash | 10,000 | 3,000 |
| Accounts receivable | - | 5,000 |
| Inventory | 62,000 | 63,000 |
| Current portion of notes receivable | 197,000 | 198,000 |
| Prepaid expenses and other current assets | 51,000 | 142,000 |
| Total current assets | 320,000 | 411,000 |
| Other intangible assets, net | 16,425,000 | 16,994,000 |
| Total assets | 16,745,000 | 17,405,000 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | 467,000 | 347,000 |
| Accrued expenses | 248,000 | 194,000 |
| Due to related party | 1,330,000 | 621,000 |
| Total current liabilities | 2,045,000 | 1,162,000 |
| Deferred tax liability, net | 688,000 | 688,000 |
| Total liabilities | 2,733,000 | 1,850,000 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.001 par value; 100,000,000 shares authorized, zero shares issued and outstanding (zero on December 31, 2025) | - | - |
| Common stock, $0.001 par value; 4,000,000,000 shares authorized, 107,821,231 shares issued and outstanding (104,621,231 on December 31, 2025) | 108,000 | 105,000 |
| Additional paid-in capital | 63,150,000 | 61,713,000 |
| Accumulated deficit | (52,492,000) | (49,507,000) |
| Total stockholders’ equity of the Company | 10,766,000 | 12,311,000 |
| Non-controlling interest in subsidiaries | 3,246,000 | 3,244,000 |
| Total stockholders’ equity | 14,012,000 | 15,555,000 |
| Total liabilities and stockholders’ equity | 16,745,000 | 17,405,000 |
Condensed Consolidated Statements of Cash Flows (Unaudited)
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss from operations | (2,983,000) | (15,631,000) |
| Adjustments to reconcile loss from operations to net cash used by operating activities: | ||
| Depreciation and amortization | 569,000 | 571,000 |
| Stock based compensation | 1,440,000 | 4,000 |
| Stock based payment for professional services received | - | 190,000 |
| Accrued interest on notes payable, related party | - | 531,000 |
| Change in fair value of note payable, related party | - | 12,942,000 |
| Decrease (increase) in assets: | ||
| Accounts receivable | 5,000 | 4,000 |
| Inventory | 1,000 | 3,000 |
| Prepaid expenses and other current assets | 91,000 | 98,000 |
| Increase (decrease) in liabilities: | ||
| Accounts payable | 120,000 | (159,000) |
| Accrued expenses | 54,000 | 71,000 |
| Due to related party | 709,000 | - |
| Net cash provided (used) by operating activities | 6,000 | (1,376,000) |
| Cash flows from investing activities: | ||
| Payments received on notes receivable | 1,000 | 1,000 |
| Net cash provided by investing activities | 1,000 | 1,000 |
| Net increase (decrease) in cash | 7,000 | (1,375,000) |
| Cash at beginning of period | 3,000 | 1,999,000 |
| Cash at end of period | 10,000 | 624,000 |
Amounts as printed on the EDGAR/iXBRL face. Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗